New research identifies two drug classes that could be re-purposed for T1D treatment

Researchers from the Indiana Biosciences Research Institute (IBRI) and Université Libre de Bruxelles (ULB) Center for Diabetes Research, identified two classes of compounds that prevent most of the effects of interferon-α (IFNα) on human beta cells, paving the way for potential future clinical trials of treatments for type 1 diabetes (T1D).